Pharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report By Product (Small Molecule, Biologics), By Drug, By Service, By Scale of Operation, By Workflow, By Application, By End Use, By Company, By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 3 Business Days
Pharmaceutical Contract Manufacturing Market Growth & Trends
The global pharmaceutical contract manufacturing market size is expected t%li%reach USD 224.51 billion by 2030, according t%li%a new report by Grand View Research, Inc. The market is anticipated t%li%grow at a CAGR of 9.84% from 2025 t%li%2030. Growth in the market can be attributed t%li%benefits offered t%li%pharmaceutical companies, such as cost efficiencies, the ability t%li%leverage contract manufacturing facilities t%li%streamline production, and the opportunity t%li%focus on core competencies. In addition, the market is driven by the increasing demand for biologics, biosimilars, high-potency active pharmaceutical ingredients (HPAPIs), and personalized medicine.
The expansion of pharmaceutical companies int%li%new product innovations has led t%li%the increased demand for contract manufacturing organization (CMO) services for clinical trials, packaging, and regulatory compliance. Technological integrations among CMOs, such as continuous manufacturing, automation, and AI-driven process optimization, are further propelling pharmaceutical production. These innovations enhance efficiency, reduce waste, and improve product quality and standards.
The pharmaceutical contract manufacturing industry is expected t%li%experience continued growth during the forecast period, as CMO providers play a crucial role in helping companies meet the regulatory requirements of the FDA, EMA, and ICH. Moreover, the growing demand for both branded and generic drugs is a significant factor in the expansion of the pharmaceutical contract manufacturing industry. As various generic drugs reach patent expiration, pharmaceutical companies are innovating new generic versions t%li%meet this demand. Hence, many of these pharmaceutical companies are relying on CMO services t%li%fulfill market needs efficiently and effectively.
In addition, regulation is one of the significant factors for pharmaceutical products that have fueled the demand for pharmaceutical contract manufacturing. The FDA plays a pivotal role in ensuring the safety and efficiency of pharmaceuticals in the market. Likewise, strategic partnerships and accelerating product launches drive market growth. For instance, in December 2024, Lonza mentioned the expansion of its service offering orally delivered biologic therapies t%li%support innovative capsule companies' unique development and manufacturing needs. The product launch will help patients explore innovative delivery solutions t%li%mitigate bioavailability challenges.
Pharmaceutical Contract Manufacturing Market Report Highlights
Pharmaceutical Contract Manufacturing Market Growth & Trends
The global pharmaceutical contract manufacturing market size is expected t%li%reach USD 224.51 billion by 2030, according t%li%a new report by Grand View Research, Inc. The market is anticipated t%li%grow at a CAGR of 9.84% from 2025 t%li%2030. Growth in the market can be attributed t%li%benefits offered t%li%pharmaceutical companies, such as cost efficiencies, the ability t%li%leverage contract manufacturing facilities t%li%streamline production, and the opportunity t%li%focus on core competencies. In addition, the market is driven by the increasing demand for biologics, biosimilars, high-potency active pharmaceutical ingredients (HPAPIs), and personalized medicine.
The expansion of pharmaceutical companies int%li%new product innovations has led t%li%the increased demand for contract manufacturing organization (CMO) services for clinical trials, packaging, and regulatory compliance. Technological integrations among CMOs, such as continuous manufacturing, automation, and AI-driven process optimization, are further propelling pharmaceutical production. These innovations enhance efficiency, reduce waste, and improve product quality and standards.
The pharmaceutical contract manufacturing industry is expected t%li%experience continued growth during the forecast period, as CMO providers play a crucial role in helping companies meet the regulatory requirements of the FDA, EMA, and ICH. Moreover, the growing demand for both branded and generic drugs is a significant factor in the expansion of the pharmaceutical contract manufacturing industry. As various generic drugs reach patent expiration, pharmaceutical companies are innovating new generic versions t%li%meet this demand. Hence, many of these pharmaceutical companies are relying on CMO services t%li%fulfill market needs efficiently and effectively.
In addition, regulation is one of the significant factors for pharmaceutical products that have fueled the demand for pharmaceutical contract manufacturing. The FDA plays a pivotal role in ensuring the safety and efficiency of pharmaceuticals in the market. Likewise, strategic partnerships and accelerating product launches drive market growth. For instance, in December 2024, Lonza mentioned the expansion of its service offering orally delivered biologic therapies t%li%support innovative capsule companies' unique development and manufacturing needs. The product launch will help patients explore innovative delivery solutions t%li%mitigate bioavailability challenges.
Pharmaceutical Contract Manufacturing Market Report Highlights
- The API manufacturing segment dominated the market with a share of 70.68% in 2024. Growth in the segment can be attributed t%li%increasing HPAPI production, rising demand for continuous API manufacturing, growing FDA approval for the market, and the launch of new products.
- Based on product, the small molecule segment held the largest market share in 2024, which is attributed t%li%the increasing demand for generics, specialty drugs, and HPAPIs, and growing innovations of drugs have enhanced the requirement for CMO’s efficiency, scalability, and regulatory compliance further driving the market growth.
- The generics segment dominated the market in 2024 owing t%li%the increasing prevalence of chronic diseases, growing patent expirations, and rising demand for cost-efficient drugs.
- Based on scale of operation, the batch segment dominated the market. It accounted for 88.88% in 2024, attributing t%li%various benefits such as batch production and major support for saving operational costs.
- The commercial segment dominated the market in 2024. Growth in this segment can be attributed t%li%the increasing launch of various products that help treat diseases.
- The oncology segment held the largest market share in 2024 based on application. This segment is driven by increasing cancer incidences and new pharmaceutical drug requirements.
- The pharmaceutical companies segment held the largest market share in 2024 based on end-use. Pharmaceutical companies utilize contract manufacturing t%li%lower costs, increase scalability, and speed up time-to-market. CMOs offer expertise in API synthesis, formulation, and regulatory compliance. In addition, outsourcing provides access t%li%advanced technologies, flexible production capacity, and optimized global supply chains.
- The small company size segment dominated the market in 2024 due t%li%increasing employee strengths, facilities, and venture funding.
- Asia Pacific is expected t%li%register the fastest growth rate of 10.80% CAGR over the forecast period. Due t%li%the rising number of pharmaceutical companies & contract manufacturing organizations in countries like Japan, China, and India, Asia Pacific will likely witness rapid growth over the estimated time. Furthermore, the availability of a skilled workforce within the region at a lower cost compared t%li%the U.S. is another factor that is anticipated t%li%propel the market growth.
CHAPTER 1. RESEARCH METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Service
1.2.2. Product
1.2.3. Drug
1.2.4. Scale of Operation
1.2.5. Workflow
1.2.6. Application
1.2.7. End Use
1.2.8. Company Size
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.2. Parent Market Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights
CHAPTER 3. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Technological Advancements
3.4. Clinical trials volume analysis (2024)
3.5. Pharmaceutical Contract Manufacturing Market Analysis Tools
3.5.1. Industry Analysis - Porter’s Five Analysis
3.5.2. PESTEL Analysis
3.5.3. COVID-19 Impact Analysis
CHAPTER 4. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SERVICE ESTIMATES & TREND ANALYSIS
4.1. Pharmaceutical Contract Manufacturing Market, By Service: Segment Dashboard
4.2. Pharmaceutical Contract Manufacturing Market, By Service: Movement Analysis
4.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Service, 2018 - 2030
4.4. API Manufacturing
4.4.1. API Manufacturing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Finished Drug Product Manufacturing
4.5.1. Finished Drug Product Manufacturing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.2. Oral Solids
4.5.2.1. Oral Solids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.3. Liquids
4.5.3.1. Liquids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.4. Topical
4.5.4.1. Topical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.5. Others
4.5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Packaging Services
4.6.1. Packaging Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
5.1. Pharmaceutical Contract Manufacturing Market, By Product: Segment Dashboard
5.2. Pharmaceutical Contract Manufacturing Market, By Product: Movement Analysis
5.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Product, 2018 - 2030
5.4. Small Molecule
5.4.1. Small Molecule Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Biologics
5.5.1. Biologics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.2. Monoclonal Antibodies
5.5.2.1. Monoclonal Antibodies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.3. Vaccines
5.5.3.1. Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.4. Recombinant Proteins
5.5.4.1. Recombinant Proteins Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.5. Others
5.5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DRUG ESTIMATES & TREND ANALYSIS
6.1. Pharmaceutical Contract Manufacturing Market, By Drug: Segment Dashboard
6.2. Pharmaceutical Contract Manufacturing Market, By Drug: Movement Analysis
6.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Drug, 2018 - 2030
6.4. Generics
6.4.1. Generics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Branded
6.5.1. Branded Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SCALE OF OPERATION ESTIMATES & TREND ANALYSIS
7.1. Pharmaceutical Contract Manufacturing Market, By Scale of Operation: Segment Dashboard
7.2. Pharmaceutical Contract Manufacturing Market, By Scale of Operation: Movement Analysis
7.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Scale of Operation, 2018 - 2030
7.4. Batch
7.4.1. Batch Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Continuous
7.5.1. Continuous Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 8. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: WORKFLOW ESTIMATES & TREND ANALYSIS
8.1. Pharmaceutical Contract Manufacturing Market, By Workflow: Segment Dashboard
8.2. Pharmaceutical Contract Manufacturing Market, By Workflow: Movement Analysis
8.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Workflow, 2018 - 2030
8.4. Clinical
8.4.1. Clinical Market, 2018 to 2030, (USD Million)
8.5. Commercial
8.5.1. Commercial Market, 2018 to 2030, (USD Million)
CHAPTER 9. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
9.1. Pharmaceutical Contract Manufacturing Market, By Application: Segment Dashboard
9.2. Pharmaceutical Contract Manufacturing Market, By Application: Movement Analysis
9.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Application, 2018 - 2030
9.4. Oncology
9.4.1. Oncology Market, 2018 to 2030, (USD Million)
9.5. Infectious Diseases
9.5.1. Infectious Diseases Market, 2018 to 2030, (USD Million)
9.6. Neurological Disorders
9.6.1. Neurological Disorders Market, 2018 to 2030, (USD Million)
9.7. Cardiovascular Disease
9.7.1. Cardiovascular Disease Market, 2018 to 2030, (USD Million)
9.8. Metabolic Disorders
9.8.1. Metabolic Disorders Market, 2018 to 2030, (USD Million)
9.9. Autoimmune Diseases
9.9.1. Autoimmune Diseases Market, 2018 to 2030, (USD Million)
9.10. Respiratory Diseases
9.10.1. Respiratory Diseases Market, 2018 to 2030, (USD Million)
9.11. Ophthalmology
9.11.1. Ophthalmology Market, 2018 to 2030, (USD Million)
9.12. Gastrointestinal Disorders
9.12.1. Gastrointestinal Disorders Market, 2018 to 2030, (USD Million)
9.13. Hormonal Disorders
9.13.1. Hormonal Disorders Market, 2018 to 2030, (USD Million)
9.14. Hematological Disorders
9.14.1. Hematological Disorders Market, 2018 to 2030, (USD Million)
9.15. Others
9.15.1. Others Market, 2018 to 2030, (USD Million)
CHAPTER 10. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: END USE ESTIMATES & TREND ANALYSIS
10.1. Pharmaceutical Contract Manufacturing Market, By End Use: Segment Dashboard
10.2. Pharmaceutical Contract Manufacturing Market, By End Use: Movement Analysis
10.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By End Use, 2018 - 2030
10.4. Pharmaceutical Companies
10.4.1. Pharmaceutical Companies Market, 2018 to 2030, (USD Million)
10.5. Biotechnology Companies
10.5.1. Biotechnology Companies Market, 2018 to 2030, (USD Million)
CHAPTER 11. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY SIZE ESTIMATES & TREND ANALYSIS
11.1. Pharmaceutical Contract Manufacturing Market, By Company Size: Segment Dashboard
11.2. Pharmaceutical Contract Manufacturing Market, By Company Size: Movement Analysis
11.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Company Size, 2018 - 2030
11.4. Small
11.4.1. Small Market, 2018 to 2030, (USD Million)
11.5. Medium
11.5.1. Medium Market, 2018 to 2030, (USD Million)
11.6. Large
11.6.1. Large Market, 2018 to 2030, (USD Million)
CHAPTER 12. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
12.1. Regional Market Share Analysis, 2024 & 2030
12.2. Regional Market Dashboard
12.3. Global Regional Market Snapshot
12.4. North America
12.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.4.2. U.S
12.4.2.1. Key Country Dynamics
12.4.2.2. Competitive Scenario
12.4.2.3. Regulatory Framework
12.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.4.3. Canada
12.4.3.1. Key Country Dynamics
12.4.3.2. Competitive Scenario
12.4.3.3. Regulatory Framework
12.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.4.4. Mexico
12.4.4.1. Key Country Dynamics
12.4.4.2. Competitive Scenario
12.4.4.3. Regulatory Framework
12.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5. Europe
12.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5.2. UK
12.5.2.1. Key Country Dynamics
12.5.2.2. Competitive Scenario
12.5.2.3. Regulatory Framework
12.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5.3. Germany
12.5.3.1. Key Country Dynamics
12.5.3.2. Competitive Scenario
12.5.3.3. Regulatory Framework
12.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5.4. France
12.5.4.1. Key Country Dynamics
12.5.4.2. Competitive Scenario
12.5.4.3. Regulatory Framework
12.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5.5. Italy
12.5.5.1. Key Country Dynamics
12.5.5.2. Competitive Scenario
12.5.5.3. Regulatory Framework
12.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5.6. Spain
12.5.6.1. Key Country Dynamics
12.5.6.2. Competitive Scenario
12.5.6.3. Regulatory Framework
12.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5.7. Denmark
12.5.7.1. Key Country Dynamics
12.5.7.2. Competitive Scenario
12.5.7.3. Regulatory Framework
12.5.7.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5.8. Sweden
12.5.8.1. Key Country Dynamics
12.5.8.2. Competitive Scenario
12.5.8.3. Regulatory Framework
12.5.8.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5.9. Norway
12.5.9.1. Key Country Dynamics
12.5.9.2. Competitive Scenario
12.5.9.3. Regulatory Framework
12.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.6. Asia Pacific
12.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.6.2. Japan
12.6.2.1. Key Country Dynamics
12.6.2.2. Competitive Scenario
12.6.2.3. Regulatory Framework
12.6.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.6.3. China
12.6.3.1. Key Country Dynamics
12.6.3.2. Competitive Scenario
12.6.3.3. Regulatory Framework
12.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.6.4. India
12.6.4.1. Key Country Dynamics
12.6.4.2. Competitive Scenario
12.6.4.3. Regulatory Framework
12.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.6.5. Thailand
12.6.5.1. Key Country Dynamics
12.6.5.2. Competitive Scenario
12.6.5.3. Regulatory Framework
12.6.5.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.6.6. South Korea
12.6.6.1. Key Country Dynamics
12.6.6.2. Competitive Scenario
12.6.6.3. Regulatory Framework
12.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.6.7. Australia
12.6.7.1. Key Country Dynamics
12.6.7.2. Competitive Scenario
12.6.7.3. Regulatory Framework
12.6.7.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.7. Latin America
12.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.7.2. Brazil
12.7.2.1. Key Country Dynamics
12.7.2.2. Competitive Scenario
12.7.2.3. Regulatory Framework
12.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.7.3. Argentina
12.7.3.1. Key Country Dynamics
12.7.3.2. Competitive Scenario
12.7.3.3. Regulatory Framework
12.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.8. MEA
12.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.8.2. South Africa
12.8.2.1. Key Country Dynamics
12.8.2.2. Competitive Scenario
12.8.2.3. Regulatory Framework
12.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.8.3. Saudi Arabia
12.8.3.1. Key Country Dynamics
12.8.3.2. Competitive Scenario
12.8.3.3. Regulatory Framework
12.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.8.4. UAE
12.8.4.1. Key Country Dynamics
12.8.4.2. Competitive Scenario
12.8.4.3. Regulatory Framework
12.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.8.5. Kuwait
12.8.5.1. Key Country Dynamics
12.8.5.2. Competitive Scenario
12.8.5.3. Regulatory Framework
12.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 13. COMPETITIVE LANDSCAPE
13.1. Market Participant Categorization
13.2. Company Market Share Analysis, 2023/24
13.3. Company Profiles
13.3.1. AbbVie Contract Manufacturing
13.3.1.1. Company Overview
13.3.1.2. Financial Performance
13.3.1.3. Service Benchmarking
13.3.1.4. Strategic Initiatives
13.3.2. Almac Group
13.3.2.1. Company Overview
13.3.2.2. Financial Performance
13.3.2.3. Service Benchmarking
13.3.2.4. Strategic Initiatives
13.3.3. Boehringer Ingelheim BioXcellence
13.3.3.1. Company Overview
13.3.3.2. Financial Performance
13.3.3.3. Service Benchmarking
13.3.3.4. Strategic Initiatives
13.3.4. Catalent
13.3.4.1. Company Overview
13.3.4.2. Financial Performance
13.3.4.3. Service Benchmarking
13.3.4.4. Strategic Initiatives
13.3.5. Dr. Reddy's Laboratories
13.3.5.1. Company Overview
13.3.5.2. Financial Performance
13.3.5.3. Service Benchmarking
13.3.5.4. Strategic Initiatives
13.3.6. Fareva
13.3.6.1. Company Overview
13.3.6.2. Financial Performance
13.3.6.3. Service Benchmarking
13.3.6.4. Strategic Initiatives
13.3.7. Fujifilm Diosynth Biotechnologies
13.3.7.1. Company Overview
13.3.7.2. Financial Performance
13.3.7.3. Service Benchmarking
13.3.7.4. Strategic Initiatives
13.3.8. Jubilant HollisterStier
13.3.8.1. Company Overview
13.3.8.2. Financial Performance
13.3.8.3. Service Benchmarking
13.3.8.4. Strategic Initiatives
13.3.9. Lonza Group
13.3.9.1. Company Overview
13.3.9.2. Financial Performance
13.3.9.3. Service Benchmarking
13.3.9.4. Strategic Initiatives
13.3.10. Patheon (Thermo Fisher Scientific)
13.3.10.1. Company Overview
13.3.10.2. Financial Performance
13.3.10.3. Service Benchmarking
13.3.10.4. Strategic Initiatives
13.3.11. Pfizer CentreOne
13.3.11.1. Company Overview
13.3.11.2. Financial Performance
13.3.11.3. Service Benchmarking
13.3.11.4. Strategic Initiatives
13.3.12. Prakruti Life Science
13.3.12.1. Company Overview
13.3.12.2. Financial Performance
13.3.12.3. Service Benchmarking
13.3.12.4. Strategic Initiatives
13.3.13. Recipharm
13.3.13.1. Company Overview
13.3.13.2. Financial Performance
13.3.13.3. Service Benchmarking
13.3.13.4. Strategic Initiatives
13.3.14. Samsung Biologics
13.3.14.1. Company Overview
13.3.14.2. Financial Performance
13.3.14.3. Service Benchmarking
13.3.14.4. Strategic Initiatives
13.3.15. Siegfried Holding AG
13.3.15.1. Company Overview
13.3.15.2. Financial Performance
13.3.15.3. Service Benchmarking
13.3.15.4. Strategic Initiatives
13.3.16. Vetter Pharma
13.3.16.1. Company Overview
13.3.16.2. Financial Performance
13.3.16.3. Service Benchmarking
13.3.16.4. Strategic Initiatives
13.3.17. WuXi AppTec
13.3.17.1. Company Overview
13.3.17.2. Financial Performance
13.3.17.3. Service Benchmarking
13.3.17.4. Strategic Initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Service
1.2.2. Product
1.2.3. Drug
1.2.4. Scale of Operation
1.2.5. Workflow
1.2.6. Application
1.2.7. End Use
1.2.8. Company Size
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.2. Parent Market Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights
CHAPTER 3. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Technological Advancements
3.4. Clinical trials volume analysis (2024)
3.5. Pharmaceutical Contract Manufacturing Market Analysis Tools
3.5.1. Industry Analysis - Porter’s Five Analysis
3.5.2. PESTEL Analysis
3.5.3. COVID-19 Impact Analysis
CHAPTER 4. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SERVICE ESTIMATES & TREND ANALYSIS
4.1. Pharmaceutical Contract Manufacturing Market, By Service: Segment Dashboard
4.2. Pharmaceutical Contract Manufacturing Market, By Service: Movement Analysis
4.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Service, 2018 - 2030
4.4. API Manufacturing
4.4.1. API Manufacturing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Finished Drug Product Manufacturing
4.5.1. Finished Drug Product Manufacturing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.2. Oral Solids
4.5.2.1. Oral Solids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.3. Liquids
4.5.3.1. Liquids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.4. Topical
4.5.4.1. Topical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.5. Others
4.5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Packaging Services
4.6.1. Packaging Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
5.1. Pharmaceutical Contract Manufacturing Market, By Product: Segment Dashboard
5.2. Pharmaceutical Contract Manufacturing Market, By Product: Movement Analysis
5.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Product, 2018 - 2030
5.4. Small Molecule
5.4.1. Small Molecule Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Biologics
5.5.1. Biologics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.2. Monoclonal Antibodies
5.5.2.1. Monoclonal Antibodies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.3. Vaccines
5.5.3.1. Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.4. Recombinant Proteins
5.5.4.1. Recombinant Proteins Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.5. Others
5.5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DRUG ESTIMATES & TREND ANALYSIS
6.1. Pharmaceutical Contract Manufacturing Market, By Drug: Segment Dashboard
6.2. Pharmaceutical Contract Manufacturing Market, By Drug: Movement Analysis
6.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Drug, 2018 - 2030
6.4. Generics
6.4.1. Generics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Branded
6.5.1. Branded Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SCALE OF OPERATION ESTIMATES & TREND ANALYSIS
7.1. Pharmaceutical Contract Manufacturing Market, By Scale of Operation: Segment Dashboard
7.2. Pharmaceutical Contract Manufacturing Market, By Scale of Operation: Movement Analysis
7.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Scale of Operation, 2018 - 2030
7.4. Batch
7.4.1. Batch Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Continuous
7.5.1. Continuous Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 8. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: WORKFLOW ESTIMATES & TREND ANALYSIS
8.1. Pharmaceutical Contract Manufacturing Market, By Workflow: Segment Dashboard
8.2. Pharmaceutical Contract Manufacturing Market, By Workflow: Movement Analysis
8.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Workflow, 2018 - 2030
8.4. Clinical
8.4.1. Clinical Market, 2018 to 2030, (USD Million)
8.5. Commercial
8.5.1. Commercial Market, 2018 to 2030, (USD Million)
CHAPTER 9. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
9.1. Pharmaceutical Contract Manufacturing Market, By Application: Segment Dashboard
9.2. Pharmaceutical Contract Manufacturing Market, By Application: Movement Analysis
9.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Application, 2018 - 2030
9.4. Oncology
9.4.1. Oncology Market, 2018 to 2030, (USD Million)
9.5. Infectious Diseases
9.5.1. Infectious Diseases Market, 2018 to 2030, (USD Million)
9.6. Neurological Disorders
9.6.1. Neurological Disorders Market, 2018 to 2030, (USD Million)
9.7. Cardiovascular Disease
9.7.1. Cardiovascular Disease Market, 2018 to 2030, (USD Million)
9.8. Metabolic Disorders
9.8.1. Metabolic Disorders Market, 2018 to 2030, (USD Million)
9.9. Autoimmune Diseases
9.9.1. Autoimmune Diseases Market, 2018 to 2030, (USD Million)
9.10. Respiratory Diseases
9.10.1. Respiratory Diseases Market, 2018 to 2030, (USD Million)
9.11. Ophthalmology
9.11.1. Ophthalmology Market, 2018 to 2030, (USD Million)
9.12. Gastrointestinal Disorders
9.12.1. Gastrointestinal Disorders Market, 2018 to 2030, (USD Million)
9.13. Hormonal Disorders
9.13.1. Hormonal Disorders Market, 2018 to 2030, (USD Million)
9.14. Hematological Disorders
9.14.1. Hematological Disorders Market, 2018 to 2030, (USD Million)
9.15. Others
9.15.1. Others Market, 2018 to 2030, (USD Million)
CHAPTER 10. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: END USE ESTIMATES & TREND ANALYSIS
10.1. Pharmaceutical Contract Manufacturing Market, By End Use: Segment Dashboard
10.2. Pharmaceutical Contract Manufacturing Market, By End Use: Movement Analysis
10.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By End Use, 2018 - 2030
10.4. Pharmaceutical Companies
10.4.1. Pharmaceutical Companies Market, 2018 to 2030, (USD Million)
10.5. Biotechnology Companies
10.5.1. Biotechnology Companies Market, 2018 to 2030, (USD Million)
CHAPTER 11. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY SIZE ESTIMATES & TREND ANALYSIS
11.1. Pharmaceutical Contract Manufacturing Market, By Company Size: Segment Dashboard
11.2. Pharmaceutical Contract Manufacturing Market, By Company Size: Movement Analysis
11.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Company Size, 2018 - 2030
11.4. Small
11.4.1. Small Market, 2018 to 2030, (USD Million)
11.5. Medium
11.5.1. Medium Market, 2018 to 2030, (USD Million)
11.6. Large
11.6.1. Large Market, 2018 to 2030, (USD Million)
CHAPTER 12. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
12.1. Regional Market Share Analysis, 2024 & 2030
12.2. Regional Market Dashboard
12.3. Global Regional Market Snapshot
12.4. North America
12.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.4.2. U.S
12.4.2.1. Key Country Dynamics
12.4.2.2. Competitive Scenario
12.4.2.3. Regulatory Framework
12.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.4.3. Canada
12.4.3.1. Key Country Dynamics
12.4.3.2. Competitive Scenario
12.4.3.3. Regulatory Framework
12.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.4.4. Mexico
12.4.4.1. Key Country Dynamics
12.4.4.2. Competitive Scenario
12.4.4.3. Regulatory Framework
12.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5. Europe
12.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5.2. UK
12.5.2.1. Key Country Dynamics
12.5.2.2. Competitive Scenario
12.5.2.3. Regulatory Framework
12.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5.3. Germany
12.5.3.1. Key Country Dynamics
12.5.3.2. Competitive Scenario
12.5.3.3. Regulatory Framework
12.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5.4. France
12.5.4.1. Key Country Dynamics
12.5.4.2. Competitive Scenario
12.5.4.3. Regulatory Framework
12.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5.5. Italy
12.5.5.1. Key Country Dynamics
12.5.5.2. Competitive Scenario
12.5.5.3. Regulatory Framework
12.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5.6. Spain
12.5.6.1. Key Country Dynamics
12.5.6.2. Competitive Scenario
12.5.6.3. Regulatory Framework
12.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5.7. Denmark
12.5.7.1. Key Country Dynamics
12.5.7.2. Competitive Scenario
12.5.7.3. Regulatory Framework
12.5.7.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5.8. Sweden
12.5.8.1. Key Country Dynamics
12.5.8.2. Competitive Scenario
12.5.8.3. Regulatory Framework
12.5.8.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.5.9. Norway
12.5.9.1. Key Country Dynamics
12.5.9.2. Competitive Scenario
12.5.9.3. Regulatory Framework
12.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.6. Asia Pacific
12.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.6.2. Japan
12.6.2.1. Key Country Dynamics
12.6.2.2. Competitive Scenario
12.6.2.3. Regulatory Framework
12.6.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.6.3. China
12.6.3.1. Key Country Dynamics
12.6.3.2. Competitive Scenario
12.6.3.3. Regulatory Framework
12.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.6.4. India
12.6.4.1. Key Country Dynamics
12.6.4.2. Competitive Scenario
12.6.4.3. Regulatory Framework
12.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.6.5. Thailand
12.6.5.1. Key Country Dynamics
12.6.5.2. Competitive Scenario
12.6.5.3. Regulatory Framework
12.6.5.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.6.6. South Korea
12.6.6.1. Key Country Dynamics
12.6.6.2. Competitive Scenario
12.6.6.3. Regulatory Framework
12.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.6.7. Australia
12.6.7.1. Key Country Dynamics
12.6.7.2. Competitive Scenario
12.6.7.3. Regulatory Framework
12.6.7.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.7. Latin America
12.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.7.2. Brazil
12.7.2.1. Key Country Dynamics
12.7.2.2. Competitive Scenario
12.7.2.3. Regulatory Framework
12.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.7.3. Argentina
12.7.3.1. Key Country Dynamics
12.7.3.2. Competitive Scenario
12.7.3.3. Regulatory Framework
12.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.8. MEA
12.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.8.2. South Africa
12.8.2.1. Key Country Dynamics
12.8.2.2. Competitive Scenario
12.8.2.3. Regulatory Framework
12.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.8.3. Saudi Arabia
12.8.3.1. Key Country Dynamics
12.8.3.2. Competitive Scenario
12.8.3.3. Regulatory Framework
12.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.8.4. UAE
12.8.4.1. Key Country Dynamics
12.8.4.2. Competitive Scenario
12.8.4.3. Regulatory Framework
12.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
12.8.5. Kuwait
12.8.5.1. Key Country Dynamics
12.8.5.2. Competitive Scenario
12.8.5.3. Regulatory Framework
12.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 13. COMPETITIVE LANDSCAPE
13.1. Market Participant Categorization
13.2. Company Market Share Analysis, 2023/24
13.3. Company Profiles
13.3.1. AbbVie Contract Manufacturing
13.3.1.1. Company Overview
13.3.1.2. Financial Performance
13.3.1.3. Service Benchmarking
13.3.1.4. Strategic Initiatives
13.3.2. Almac Group
13.3.2.1. Company Overview
13.3.2.2. Financial Performance
13.3.2.3. Service Benchmarking
13.3.2.4. Strategic Initiatives
13.3.3. Boehringer Ingelheim BioXcellence
13.3.3.1. Company Overview
13.3.3.2. Financial Performance
13.3.3.3. Service Benchmarking
13.3.3.4. Strategic Initiatives
13.3.4. Catalent
13.3.4.1. Company Overview
13.3.4.2. Financial Performance
13.3.4.3. Service Benchmarking
13.3.4.4. Strategic Initiatives
13.3.5. Dr. Reddy's Laboratories
13.3.5.1. Company Overview
13.3.5.2. Financial Performance
13.3.5.3. Service Benchmarking
13.3.5.4. Strategic Initiatives
13.3.6. Fareva
13.3.6.1. Company Overview
13.3.6.2. Financial Performance
13.3.6.3. Service Benchmarking
13.3.6.4. Strategic Initiatives
13.3.7. Fujifilm Diosynth Biotechnologies
13.3.7.1. Company Overview
13.3.7.2. Financial Performance
13.3.7.3. Service Benchmarking
13.3.7.4. Strategic Initiatives
13.3.8. Jubilant HollisterStier
13.3.8.1. Company Overview
13.3.8.2. Financial Performance
13.3.8.3. Service Benchmarking
13.3.8.4. Strategic Initiatives
13.3.9. Lonza Group
13.3.9.1. Company Overview
13.3.9.2. Financial Performance
13.3.9.3. Service Benchmarking
13.3.9.4. Strategic Initiatives
13.3.10. Patheon (Thermo Fisher Scientific)
13.3.10.1. Company Overview
13.3.10.2. Financial Performance
13.3.10.3. Service Benchmarking
13.3.10.4. Strategic Initiatives
13.3.11. Pfizer CentreOne
13.3.11.1. Company Overview
13.3.11.2. Financial Performance
13.3.11.3. Service Benchmarking
13.3.11.4. Strategic Initiatives
13.3.12. Prakruti Life Science
13.3.12.1. Company Overview
13.3.12.2. Financial Performance
13.3.12.3. Service Benchmarking
13.3.12.4. Strategic Initiatives
13.3.13. Recipharm
13.3.13.1. Company Overview
13.3.13.2. Financial Performance
13.3.13.3. Service Benchmarking
13.3.13.4. Strategic Initiatives
13.3.14. Samsung Biologics
13.3.14.1. Company Overview
13.3.14.2. Financial Performance
13.3.14.3. Service Benchmarking
13.3.14.4. Strategic Initiatives
13.3.15. Siegfried Holding AG
13.3.15.1. Company Overview
13.3.15.2. Financial Performance
13.3.15.3. Service Benchmarking
13.3.15.4. Strategic Initiatives
13.3.16. Vetter Pharma
13.3.16.1. Company Overview
13.3.16.2. Financial Performance
13.3.16.3. Service Benchmarking
13.3.16.4. Strategic Initiatives
13.3.17. WuXi AppTec
13.3.17.1. Company Overview
13.3.17.2. Financial Performance
13.3.17.3. Service Benchmarking
13.3.17.4. Strategic Initiatives
